Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS CRO Intellim to Collaborate with Indian Firm for CDISC
December 18, 2014
-
REGULATORY LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
-
BUSINESS Battle Begins for Blopress Generics
December 16, 2014
-
REGULATORY LDP Healthcare Big Names Cruise to Victory in Lower House Poll
December 15, 2014
-
REGULATORY Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
-
REGULATORY Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
-
REGULATORY Annual NHI Price Cuts Draw Fire from All Sides at Ryukaikon Council
December 10, 2014
-
REGULATORY Japan NIH to Have Drug Discovery Support Unit
December 9, 2014
-
BUSINESS April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
-
BUSINESS Daiichi Sankyo to Harness Ties with Cardiologists in Lixiana Promotion
December 8, 2014
-
BUSINESS Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
-
REGULATORY ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
-
REGULATORY Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
December 3, 2014
-
BUSINESS Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
-
BUSINESS Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
-
BUSINESS A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
-
REGULATORY PAFSC’s Second Committee Backs Approval of Novartis’s Secukinumab
December 1, 2014
-
BUSINESS EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
-
INTERVIEW Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.
November 28, 2014
-
ACADEMIA Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official
November 27, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…